- Lobbying
- Lobbying by Maridose LLC
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Brian Wild | Senior Advisor-Office of Speaker John Boehner; Deputy Assistant for Leg Affairs- VP Cheney; Chief of Staff-Rep. Pat Toomey; Legislative Assistant- Sen. Hank Brown |
William Moschella | PrincAssocDepAG DOJ,AsstAG DOJ,ChfLegCouns/Parliam Hs Judic Comm,ChfInvestigativeCouns Hs Judic Comm,GC Hs Rules Comm,Couns Hs Judic Comm,Couns/Parliam Hs Gov Rel Comm,SrLegAsst Rep Frank Wolf,LegAsst Rep Frank Wolf,ComputerSysManager Rep Frank Wolf |
Brian McKeon | Legislative Aide Sen Boxer; Legislative Assistant Sen Boxer; Domestic Policy Advisor Sen Boxer; Senior Advisor Sen Boxer; Senior Counsel Sen Boxer; Legislative Director Senator Shaheen |
Adam Steinmetz | Policy Advisor - Committee on the Budget, United States House of Representatives |
Osiris Morel | n/a |
Melissa Kuipers Blake | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Drug Enforcement Administration (DEA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Drug Enforcement Administration (DEA)
Justice - Dept of (DOJ)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
White House Office
U.S. House of Representatives
Drug Enforcement Administration (DEA)
Justice - Dept of (DOJ)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
White House Office
U.S. House of Representatives
Drug Enforcement Administration (DEA)
Justice - Dept of (DOJ)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Justice - Dept of (DOJ)
White House Office
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Office of Management & Budget (OMB)
Drug Enforcement Administration (DEA)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Justice - Dept of (DOJ)
White House Office
Office of Management & Budget (OMB)
Drug Enforcement Administration (DEA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Justice - Dept of (DOJ)
White House Office
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Justice - Dept of (DOJ)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Office of Management & Budget (OMB)
Office of the Vice President of the United States
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Drug Enforcement Administration (DEA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Type of Issue
Registration
Issue(s) they said they’d lobby about: Medical research.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate